Mabion S.A.

Mabion believes the next generation of biologics will be built through strong partnerships and shared ambition. We are looking to collaborate with companies ready to co-create high-value biosimilar programs and new therapeutic solutions through flexible models including early licensing, co-development, risk-sharing, asset-focused partnerships and broader strategic alliances.

Our vision is to combine complementary capabilities from the earliest stages scientific expertise, biologics development, process and analytical capabilities, regulatory know-how and large molecule manufacturing to turn promising ideas into differentiated products faster, with greater efficiency and shared value.

We are also open to co-creating next-generation ADC linker technologies designed to improve stability, payload delivery and manufacturability, as well as differentiated ADC concepts.

We welcome innovative opportunities around CD20-targeting approaches in rare and orphan diseases, where B-cell modulation could open new therapeutic possibilities beyond established indications.

Mabion is a public company listed on the Warsaw Stock Exchange (WSE: MAB). More: www.mabion.eu.